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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1665Patent Foramen Ovale: The Known and the To Be KnownShelby Kutty, Partho P. Sengupta, Bijoy K. Khandheria
The patent foramen ovale (PFO) is a normal interatrial communication during fetal life that
persists after birth in approximately 1 in every 4 adults. Though there is compelling
circumstantial evidence implicating PFO as a route for embolic transit from the systemic
circulation to the brain, the precise role of PFO in the pathogenesis of cryptogenic stroke is
not yet established. Several randomized trials of transcatheter PFO closure versus medical
management are ongoing, but to date there is no clear benefit to either strategy. Other trials
have shown equivalency for anticoagulation and antiplatelet therapies.CLINICAL RESEARCH TRANSCATHETER AORTIC VALVE REPLACEMENT1672Study Confirms Improvements in Health-Related Quality of Life After TAVITimothy A. Fairbairn, David M. Meads, Adam N. Mather, Manish Motwani, Sue Pavitt, Sven Plein,
Daniel J. Blackman, John P. Greenwood
Health-related quality of life (HRQOL) is an important outcome measure, for which there is
limited evidence in transcatheter aortic valve implantation (TAVI) populations. Fairbairn and
colleagues administered 2 HRQOL questionnaires at baseline, 30 days, 6 months, and
12 months after TAVI to 102 subjects. HRQOL significantly improved over 12 months at
which time it was similar to age-adjusted U.S. population norms. The greatest change
occurred from baseline to 30 days. HRQOL significantly improves early following TAVI and
is maintained out to at least 1 year.(continued on page A-22)
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1681Reloading of Prasugrel May Be Necessary
Prior to PCI in Patients on Maintenance DoseAntonio Tello-Montoliu, Salvatore D. Tomasello, José Luis Ferreiro, Masafumi Ueno, Naveen Seecheran,
Bhaloo Desai, Murali Kodali, Ronald K. Charlton, Lyndon C. Box, Martin M. Zenni, Luis A. Guzman,
Theodore A. Bass, Dominick J. Angiolillo
Tello-Montoliu and colleagues calculated the pharmacodynamic (PD) effects of different
prasugrel loading doses in patients on chronic prasugrel therapy. This was a prospective PD
study in 64 patients on maintenance prasugrel therapy (10 mg/day) randomized to a 10-mg,
30-mg, or 60-mg dose of prasugrel. The 60-mg dose reduced the platelet reactivity index
after 1 and 4 h, and was superior to either 30 mg or 10 mg at 4 h. Similar results were
obtained with other P2Y12 specific assays. In patients on maintenance prasugrel therapy,
reloading with a 60-mg dose should be considered prior to percutaneous coronary
intervention.CARDIOVASCULAR RISK1688Serum Fetuin-A Levels and the Risk of CVD MortalityGail A. Laughlin, Kevin Cummins, Christina L. Wassel, Lori B. Daniels, Joachim H. Ix
Fetuin-A acts as an inhibitor of calcification by increasing the blood solubility of calcium and
phosphorus. It also binds directly to the insulin receptor and induces insulin resistance. In this
population-based prospective study of 633 men and 1,025 women, fetuin-A levels and
cardiovascular disease (CVD) risk factors were measured in 1992 to 1996 and the subjects
were followed for vital status through 2010. The association of fetuin-A with CVD mortality
differed by diabetes status; for participants without diabetes, the risk of CVD mortality was
highest for those in the lowest quartile. For participants with diabetes, the opposite was true
with risk of CVD mortality being lowest for those in the lowest quartile.CARDIOVASCULAR RISK1697Resistin, an Adipokine Associated With Obesity, Regulates LDL Receptor ActivityMichelle Melone, Larissa Wilsie, Oksana Palyha, Alison Strack, Shirya Rashid
Serum levels of the adipose tissue adipokine, resistin, are increased in human obesity and have
been linked to cardiovascular risk. Melone and colleagues investigated the role resistin plays in
regulating the uptake of atherogenic low-density lipoproteins (LDL) in human hepatocytes.
In a series of experiments using cultured human hepatocytes, resistin downregulated
hepatocyte LDL receptor expression by 40%. This was at least partially due to increased
expression of the protease, PCSK9, which enhances intracellular LDL receptor degradation.
These results, suggesting that lowering resistin levels or blocking its effects, should be
considered as a method for reducing LDL levels, particularly in obese patients.
Editorial Comment: Sergio Fazio, MacRae F. Linton, page 1706(continued on page A-24)
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1709Cockroft-Gault Superior to Other Formulas for
Relationship Between Renal Function and Mortality in CHF PatientsElisabet Zamora, Josep Lupo´n, Joan Vila, Agustı´n Urrutia, Marta de Antonio, Hèctor Sanz, Maria Grau,
Jordi Ara, Antoni Bayés-Genı´s
There are 3 widely formulas used for calculating estimated glomerular filtration rate (eGFR):
Cockroft-Gault formula, Modification of Diet in Renal Disease Study-4, and the Chronic
Kidney Disease Epidemiology Collaboration. Zamora and colleagues compared the utility of
these 3 formulas for predicting the risk of death in ambulatory patients with systolic heart
failure. A total of 925 patients with a mean left ventricular ejection fraction of 31% were
studied with a mean follow-up of 3.5 years. All 3 formulas afforded independent prognostic
information, but risk prediction was most accurate using the Cockroft-Gault formula with a net
reclassification improvement of 21%. The Cockroft-Gault formula [(140  age in years) 
weight in kilograms/(72  serum creatinine level in mg/dl) adjusted by sex ( 0.85 in
women) and indexed to body surface area] provides the most useful prognostic
information relating eGFR to mortality.Editorial Comment: Robert W. Schrier, Dmitri Shchekochikhin, page 1716CARDIAC IMAGING1719Meta-Analysis Compares Diagnostic Performance of SPECT, PET, and CMRCaroline Jaarsma, Tim Leiner, Sebastiaan C. Bekkers, Harry J. Crijns, Joachim E. Wildberger, Eike Nagel,
Patricia J. Nelemans, Simon Schalla
Jaarsma and colleagues performed a meta-analysis to determine the diagnostic accuracy of
single-photon emission computed tomography (SPECT), cardiac magnetic resonance
(CMR), and positron emission tomography (PET) perfusion imaging. A total of 166 articles
compared the diagnostic performance for detecting a (50% diameter stenosis) on coronary
angiography. Patient-based analysis demonstrated similar sensitivities for SPECT, CMR, and
PET with specificities of 61%, 76%, and 81%, respectively. The diagnostic odds ratio were
15.3, 26.4, and 36.5, respectively. In summary, all 3 modalities have high sensitivity, but PET
has the highest diagnostic performance. The authors conclude that referring physicians should
consider these findings in the context of local expertise and infrastructure.
